SG, Elpis Biopharmaceuticals to research allogeneic CAR technologies

It aims to develop potent and durable cell therapies for acute myeloid leukemia and multiple myeloma.

Singapore General Hospital (SGH) and Elpis Biopharmaceuticals, a clinical-stage cell therapy company, have entered into a research collaboration on the development of allogeneic CAR technologies.

This includes an armoured CAR-γδT (gamma-delta-T), targeting acute myeloid leukaemia (AML) and a bi-specific CAR-γδT for multiple myeloma (MM).

Under the terms of the agreement, Elpis will contribute the bi-specific and armoured CAR technologies to SGH via a technology transfer, whilst the SGH will leverage its unique γδT platform and clinical expertise to advance the development of each asset into separate investigator-initiated trials.

"We aim to develop potent and durable cell therapies for AML and MM and by leveraging robust immune modulation, our goal is to enhance antitumor activity," said Assistant Professor Chen Yunxin, Senior Consultant, Department of Haematology, and study clinical lead at SGH.